Li X, Gao P, Niu J
Biomed Res Int. 2019; 2019:8764093.
PMID: 31531370
PMC: 6720367.
DOI: 10.1155/2019/8764093.
Dattaroy D, Seth R, Sarkar S, Kimono D, Albadrani M, Chandrashekaran V
Eur J Pharmacol. 2018; 841:33-48.
PMID: 30194936
PMC: 7193950.
DOI: 10.1016/j.ejphar.2018.08.040.
Haczeyni F, Wang H, Barn V, Mridha A, Yeh M, Haigh W
Hepatol Commun. 2018; 1(7):663-674.
PMID: 29404484
PMC: 5721439.
DOI: 10.1002/hep4.1072.
Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi L
World J Gastroenterol. 2017; 23(36):6571-6592.
PMID: 29085206
PMC: 5643282.
DOI: 10.3748/wjg.v23.i36.6571.
Massart J, Begriche K, Moreau C, Fromenty B
J Clin Transl Res. 2017; 3(Suppl 1):212-232.
PMID: 28691103
PMC: 5500243.
DOI: 10.18053/jctres.03.2017S1.006.
Effect of cholecystectomy on hepatic fat accumulation and insulin resistance in non-obese Hispanic patients: a pilot study.
Cortes V, Quezada N, Uribe S, Arrese M, Nervi F
Lipids Health Dis. 2017; 16(1):129.
PMID: 28666456
PMC: 5493064.
DOI: 10.1186/s12944-017-0525-3.
Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation.
Dattaroy D, Seth R, Das S, Alhasson F, Chandrashekaran V, Michelotti G
Am J Physiol Gastrointest Liver Physiol. 2016; 310(7):G510-25.
PMID: 26718771
PMC: 4824178.
DOI: 10.1152/ajpgi.00259.2015.
Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH.
Montesi L, Mazzotti A, Moscatiello S, Forlani G, Marchesini G
Hepatol Int. 2015; 7 Suppl 2:814-22.
PMID: 26202296
DOI: 10.1007/s12072-013-9451-2.
Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseases.
Guo B, Li Z
Front Genet. 2014; 5:242.
PMID: 25120559
PMC: 4110625.
DOI: 10.3389/fgene.2014.00242.
Controversies in the Diagnosis and Management of NAFLD and NASH.
Rinella M, Loomba R, Caldwell S, Kowdley K, Charlton M, Tetri B
Gastroenterol Hepatol (N Y). 2014; 10(4):219-27.
PMID: 24976805
PMC: 4073533.
Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices.
Szalowska E, van der Burg B, Man H, Hendriksen P, Peijnenburg A
PLoS One. 2014; 9(1):e86795.
PMID: 24489787
PMC: 3906077.
DOI: 10.1371/journal.pone.0086795.
Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications.
Del Chierico F, Gnani D, Vernocchi P, Petrucca A, Alisi A, Dallapiccola B
Int J Mol Sci. 2014; 15(1):684-711.
PMID: 24402126
PMC: 3907832.
DOI: 10.3390/ijms15010684.
Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders.
Reddy S, Zhan M, Alexander H, El-Kamary S
World J Gastroenterol. 2013; 19(45):8301-11.
PMID: 24363521
PMC: 3857453.
DOI: 10.3748/wjg.v19.i45.8301.
EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD.
Vella S, Gnani D, Crudele A, Ceccarelli S, De Stefanis C, Gaspari S
Int J Mol Sci. 2013; 14(12):24154-68.
PMID: 24351808
PMC: 3876102.
DOI: 10.3390/ijms141224154.
Transgenic mouse model harboring the transcriptional fusion ccl20-luciferase as a novel reporter of pro-inflammatory response.
Crispo M, Van Maele L, Tabareau J, Cayet D, Errea A, Ferreira A
PLoS One. 2013; 8(11):e78447.
PMID: 24265691
PMC: 3827052.
DOI: 10.1371/journal.pone.0078447.
Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease.
Li M, Shen Z, Li Y
World J Gastroenterol. 2013; 19(41):7024-31.
PMID: 24222944
PMC: 3819536.
DOI: 10.3748/wjg.v19.i41.7024.
Immune cells and metabolic dysfunction.
Eheim A, Medrikova D, Herzig S
Semin Immunopathol. 2013; 36(1):13-25.
PMID: 24212254
DOI: 10.1007/s00281-013-0403-7.
The global NAFLD epidemic.
Loomba R, Sanyal A
Nat Rev Gastroenterol Hepatol. 2013; 10(11):686-90.
PMID: 24042449
DOI: 10.1038/nrgastro.2013.171.